Favezelimab/pembrolizumab
| Combination of | |
|---|---|
| Favezelimab | Anti–LAG-3 monoclonal antibody |
| Pembrolizumab | Anti-PD-1 monoclonal antibody |
| Legal status | |
| Legal status |
|
Favezelimab/pembrolizumab is a fixed-dose combination of two monoclonal antibodies developed by Merck to treat various cancers.[1][2][3][4][5]
References
[edit]- ^ Timmerman, John; Lavie, David; Johnson, Nathalie A.; Avigdor, Abraham; Borchmann, Peter; Andreadis, Charalambos; Bazargan, Ali; Gregory, Gareth P.; Keane, Colm; Tsoran-Rosenthal, Inna; Vucinic, Vladan; Zinzani, Pier Luigi; West, Rachel Marceau; Pillai, Pallavi; Nahar, Akash; Herrera, Alex F. (15 November 2022). "Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment". Blood. 140 (Supplement 1): 768–770. doi:10.1182/blood-2022-166670. S2CID 260785891.
- ^ Timmerman, John; Lavie, David; Johnson, Nathalie A.; Avigdor, Abraham; Borchmann, Peter; Andreadis, Charalambos; Bazargan, Ali; Gregory, Gareth; Keane, Colm; Inna, Tzoran; Vucinic, Vladan; Zinzani, Pier Luigi; Zhang, Hong; Pillai, Pallavi; Marinello, Patricia; Herrera, Alex Francisco (1 June 2022). "Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study". Journal of Clinical Oncology. 40 (16_suppl): 7545. doi:10.1200/JCO.2022.40.16_suppl.7545. S2CID 249445835.
- ^ Garralda, E.; Sukari, A.; Lakhani, N.J.; Patnaik, A.; Lou, Y.; Im, S.-A.; Golan, T.; Geva, R.; Wermke, M.; de Miguel, M.; Palcza, J.; Jha, S.; Chaney, M.; Abraham, A.K.; Healy, J.; Falchook, G.S. (December 2022). "A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer". ESMO Open. 7 (6): 100639. doi:10.1016/j.esmoop.2022.100639. PMC 9832734. PMID 36493599.
- ^ Rha, Sun Young; Miller, Wilson H.; de Miguel, María José; Im, Seock-Ah; Lugowska, Iwona; Wermke, Martin; Kotani, Daisuke; Bauer, Todd Michael; Takashima, Atsuo; Palcza, John; Chaney, Marya F.; Dobrenkov, Konstantin; Garralda, Elena (1 February 2023). "Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer". Journal of Clinical Oncology. 41 (4_suppl): 394. doi:10.1200/JCO.2023.41.4_suppl.394. S2CID 256265890.
- ^ Garralda, Elena; Sukari, Ammar; Lakhani, Nehal J.; Patnaik, Amita; Lou, Yanyan; Im, Seock-Ah; Golan, Talia; Geva, Ravit; Wermke, Martin; De Miguel, Maria; Palcza, John; Jha, Sujata; Chaney, Marya F.; Healy, Jane Anne; Falchook, Gerald Steven (20 May 2021). "A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer". Journal of Clinical Oncology. 39 (15_suppl): 3584. doi:10.1200/JCO.2021.39.15_suppl.3584. S2CID 236349131.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |